EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Effectiveness and safety of vedolizumab and infliximab in biologic‐naïve patients with moderate‐to‐severe ulcerative colitis: A multicenter, retrospective cohort study

Rui Ping Meng, Bao Bao Huang, Yan Ling Wei, Lin Lyu, Huan Yang, Cheng Liu, Hong Li Zhou, Xi Ping Liao, Jian Yun Zhou, Xia Xie iD

Journal of Digestive Diseases · 2024

DOI: 10.1111/1751-2980.13270 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Digestive Diseases, 2024. Verfasst von Rui Ping Meng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Xinqiao Hospital, Army Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Infliximab, Antibodies, Monoclonal, Humanized, Gastrointestinal Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Xia XIE, Cheng LIU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We conducted this multicenter, retrospective cohort study aiming to evaluate the effectiveness and safety of vedolizumab (VDZ) and infliximab (IFX) in biologic‐naïve patients with moderate‐to‐severe ulcerative colitis (UC).

Methods

Biologic‐naïve patients with moderate‐to‐severe UC who were treated with IFX or VDZ for at least 14 weeks at three tertiary hospitals in southwest China between January 2021 and January 2023 were retrospectively included. Efficacy of the biologics was evaluated based on the steroid‐free clinical remission rate, clinical remission rate, and mucosal healing rate at Weeks 14 and 52. Adverse events related to biologic use were recorded.

Results

Altogether 122 biologic‐naïve patients with moderate‐to‐severe UC were included. No marked differences in the steroid‐free clinical remission rate and clinical remission rate were observed between the two groups at Week 14 or Week 52 ( P > 0.05). The VDZ group exhibited a higher mucosal healing rate at Week 14 compared to the IFX group (33.3% vs 16.9%, P = 0.036), while that at Week 52 did not differ between the two groups (65.6% vs 47.1%, P = 0.098). There was no statistically significant difference in the rate of adverse events between the two groups ( P = 0.071).

Conclusion

VDZ and IFX showed comparable clinical efficacy and safety profiles and can be used as viable first‐line therapeutic options for biologic‐naïve patients with moderate‐to‐severe UC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeInfliximabAntibodies, Monoclonal, HumanizedGastrointestinal AgentsSeverity of Illness IndexRemission InductionHumansRetrospective StudiesFemaleMaleAdultMiddle AgedTreatment OutcomeYoung AdultChina

Stichwörter der Autor:innen

effectivenessinfliximabsafetyulcerative colitisvedolizumab

Substanzen

vedolizumabInfliximabAntibodies, Monoclonal, HumanizedGastrointestinal Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, Xinqiao Hospital, Army Medical University, Chongqing, China.
  • Department of Gastroenterology, Daping Hospital, Army Medical University, Chongqing, China.
  • Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

ORCID-Profile: Xia Xie

Förderung

  • Xia XIE
  • Cheng LIU

Zitieren

APA

Meng, R. P., Huang, B. B., Wei, Y. L., Lyu, L., Yang, H., Liu, C., Zhou, H. L., Liao, X. P., Zhou, J. Y., & Xie, X. (2024). Effectiveness and safety of vedolizumab and infliximab in biologic‐naïve patients with moderate‐to‐severe ulcerative colitis: A multicenter, retrospective cohort study. Journal of Digestive Diseases. https://doi.org/10.1111/1751-2980.13270

Vancouver

Meng RP, Huang BB, Wei YL, Lyu L, Yang H, Liu C, et al. Effectiveness and safety of vedolizumab and infliximab in biologic‐naïve patients with moderate‐to‐severe ulcerative colitis: A multicenter, retrospective cohort study. Journal of Digestive Diseases. 2024. doi:10.1111/1751-2980.13270

BibTeX
@article{Meng2024,
  author = {Meng, Rui Ping and Huang, Bao Bao and Wei, Yan Ling and Lyu, Lin and Yang, Huan and Liu, Cheng and Zhou, Hong Li and Liao, Xi Ping and Zhou, Jian Yun and Xie, Xia},
  title = {Effectiveness and safety of vedolizumab and infliximab in biologic‐naïve patients with moderate‐to‐severe ulcerative colitis: A multicenter, retrospective cohort study},
  journal = {Journal of Digestive Diseases},
  year = {2024},
  doi = {10.1111/1751-2980.13270}
}
Kostenlos starten →